Pantoprazol Aptapharma (Pantoprazole)

Pantoprazole, the active ingredient in Pantoprazol Aptapharma, is a proton pump inhibitor presented as a 40 mg tablet for oral use. It reduces stomach acid production and is used to treat acid‑related disorders such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Pantoprazol Aptapharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazol Aptapharma is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related conditions: - Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Erosive esophagitis: accelerates mucosal healing and reduces symptom recurrence. - Peptic ulcer disease: supports ulcer healing and helps prevent recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the condition.

Pantoprazol Aptapharma may cause a range of adverse reactions. Most are mild and transient, but serious events can occur in rare cases.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: usually self‑limiting. - Nausea: occasional, may improve with food. - Abdominal pain: mild discomfort. - Flatulence: excess gas. - Constipation: infrequent.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): difficulty breathing, swelling of face or throat. - Clostridioides difficile infection: persistent watery diarrhoea. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat. - Bone fractures: increased risk with long‑term use. - Liver enzyme elevation: jaundice or dark urine. - Acute interstitial nephritis: reduced urine output, flank pain.

Before initiating therapy with Pantoprazol Aptapharma, consider the following safety measures: - Assess renal function: dose adjustment may be required in severe impairment. - Review hepatic status: use with caution in moderate to severe liver disease. - Evaluate for osteoporosis risk: long‑term therapy may affect bone density. - Monitor for infection: prolonged acid suppression can increase risk of gastrointestinal infections. - Pregnancy and lactation: prescribe only if clearly needed after risk‑benefit assessment. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Pantoprazol Aptapharma can affect the pharmacokinetics of several co‑administered medicines. Awareness of the interaction potential helps optimise therapy.

Major Interactions (Avoid): - Ketoconazole: markedly reduced absorption; avoid concurrent use. - Atazanavir: decreased antiviral exposure; contraindicated. - Clopidogrel: reduced antiplatelet effect; consider alternative antiplatelet.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR; monitor coagulation parameters. - Digoxin: slight increase in serum levels; check renal function and drug levels. - Methotrexate (high dose): may increase toxicity; monitor blood counts.